The Technical Analyst
GlycoMimetics Inc [GLYC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
GlycoMimetics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.09% $1.640
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 105.70 mill |
| EPS: | -0.580 |
| P/E: | -2.83 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 64.45 mill |
| Avg Daily Volume: | 0.459 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.83 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.48x |
| Company: PE -2.83 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.647 (-60.55%) $-0.993 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.410 - 1.870 ( +/- 14.02%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-29 | Junius Daniel M | Buy | 5 209 | Common Stock |
| 2024-03-29 | King Rachel K. | Buy | 3 334 | Common Stock |
| 2024-03-29 | Goldberg Mark Alan | Buy | 4 584 | Common Stock |
| 2024-01-12 | Johnson Bruce S | Buy | 250 000 | Employee Stock Option (right to buy) |
| 2024-01-12 | Semerjian Harout | Buy | 695 000 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 25.74 |
| Last 98 transactions |
| Buy: 7 229 799 | Sell: 5 299 394 |
Forecast:
16:00 - $1.640
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.640
Forecast 2: 16:00 - $1.640
Forecast 3: 16:00 - $1.640
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.640 (-4.09% ) |
| Volume | 0.964 mill |
| Avg. Vol. | 0.459 mill |
| % of Avg. Vol | 209.94 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GLYC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GLYC
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Latest Press Releases
2024-04-25 07:00:00 - Press Release
Glycomimetics To Report First Quarter 2024 Financial Results On May 9, 2024
Rockville, md.--(business wire)--glycomimetics, inc. (nasdaq: glyc), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on thursday, may 9, 2024 at 8:30 a.m. et. to access the call by phone, please go to this registration link and you will be provided with dial in details. participants are encouraged to connect 15 minutes in advance of the scheduled start time. a live webcast of the call will be available on the “investors” tab on the.
2024-03-27 07:00:00 - Press Release
Glycomimetics Reports Highlights And Financial Results For Fourth Quarter And Full Year 2023
Rockville, md.--(business wire)--glycomimetics, inc. (nasdaq: glyc), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended december 31, 2023. cash and cash equivalents as of december 31, 2023, were $41.8 million. “with the time-based analysis imminent for our pivotal phase 3 study of uproleselan in r/r aml, we are laser-focused o.
2024-03-13 07:00:00 - Press Release
Glycomimetics To Report Fourth Quarter And 2023 Full Year Financial Results On March 27, 2024
Rockville, md.--(business wire)--glycomimetics, inc. (nasdaq: glyc), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on wednesday, march 27, 2024 at 8:30 a.m. et. to access the call by phone, please go to this registration link and you will be provided with dial in details. participants are encouraged to connect 15 minutes in advance of the scheduled start time. a live webcast of the call will be available on the “inv.
2024-02-26 07:00:00 - Press Release
Glycomimetics To Participate In Upcoming Cowen 44th Annual Health Care Conference
Rockville, md.--(business wire)--glycomimetics, inc. (nasdaq: glyc) announced today that harout semerjian, chief executive officer, will participate in the leukemia panel at the cowen 44th annual health care conference in boston, ma on monday, march 4, 2024 at 12:50 p.m. et. a live webcast of the panel presentation will be available on the glycomimetics website at https://ir.glycomimetics.com/investor-relations. an archived recording will be available for 30 days following the event. about glyc.
2024-02-12 07:00:00 - Press Release
Glycomimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rockville, md.--(business wire)--glycomimetics, inc. (the “company”) (nasdaq:glyc) today announced that the compensation committee of the company's board of directors approved the grant on february 6, 2024 of a non-qualified stock option award to purchase an aggregate of 130,000 shares of the company's common stock to shantha tyavanagimatt, ph.d., the company's new senior vice president, technical operations. the award was granted as an inducement equity award outside of the company's amended a.
Latest News
2024-03-21 09:51:23 - Zacks Investment Research
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?
GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2023-11-03 12:24:06 - Seeking Alpha
GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer Edwin Rock - Chief Medical Officer Brian Hahn - Chief Financial Officer Conference Call Participants Roger Song - Jefferies Boris Peaker - TD Cowen Operator Good morning, and thank you for joining the GlycoMimetics Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode.
2023-10-20 07:00:00 - Business Wire
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November 3, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call will be available on the “Investors” tab on.
2023-09-05 07:00:00 - Business Wire
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York, NY on Wednesday, September 13, 2023 at 11:30 a.m. ET. A live webcast of the presentation will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations. An archived recording will be available for 30 days following the event. About GlycoMimet.
2023-07-19 07:00:00 - Business Wire
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, August 2, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call will be available on the “Investors” tab o.
2023-05-30 08:02:30 - Seeking Alpha
GlycoMimetics: Insider Buying Continues, And Chart Looks Healthy
GlycoMimetics' Phase 3 study of uproleselan for acute myeloid leukemia is expected to continue until early 2024, with the FDA seeking more information on survivability rates. Insider buying and technical momentum indicators suggest a bullish outlook for the company's stock, currently trading at $1.85 per share. The drug has the potential to be used in combination therapies for various cancer treatments, but investors should consider the risks and only allocate a small portion of their portfolio to GlycoMimetics.
2023-05-10 12:20:38 - Seeking Alpha
GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology
Rarely, a developmental biotech comes along with new chemistry that potentially becomes curative via transplantation. Blood cancers such as AML, MM, and MDS extract a terrible toll on patients and their loved ones.
2023-03-29 11:09:04 - Seeking Alpha
GlycoMimetics, Inc. (GLYC) Q4 2022 Earnings Call Transcript
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q4 2022 Results Conference Call March 29, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel and Company Secretary Harout Semerjian - Chief Executive Officer Brian Hahn - Chief Financial Officer Edwin Rock - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Operator Good morning. And thank you for joining the GlycoMimetics Fourth Quarter and Full Year 2022 Earnings Call.
2023-03-16 07:00:00 - Business Wire
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on Wednesday, March 29, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time.
2023-03-08 23:20:14 - Seeking Alpha
GlycoMimetics: Stock Price Drop Brings Great Speculative Trade Opportunity
Independent Data Monitoring Committee interim analysis concludes that the phase 3 study, using uproleselan in combination with chemotherapy for the treatment of relapsed/refractory AML patients should continue as planned. Last event to trigger final results from the phase 3 study, using uproleselan in combination with chemotherapy for the treatment of relapsed/refractory AML patients expected 1st half of 2024.